Cargando…

Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi

Isavuconazole, the active moiety of the water-soluble prodrug isavuconazonium sulfate, is a triazole antifungal agent used for the treatment of invasive fungal infections. The objective of this analysis was to develop a population pharmacokinetic (PPK) model to identify covariates that affect isavuc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Desai, Amit, Kovanda, Laura, Kowalski, Donna, Lu, Qiaoyang, Townsend, Robert, Bonate, Peter L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2016
Materias:	Clinical Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997882/ https://www.ncbi.nlm.nih.gov/pubmed/27381396 http://dx.doi.org/10.1128/AAC.02819-15

Ejemplares similares

Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi
por: Desai, Amit V., et al.
Publicado: (2017)

Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)
por: Kovanda, Laura L., et al.
Publicado: (2016)

Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics
por: Townsend, Robert W., et al.
Publicado: (2017)

2535. Physiological-based pharmacokinetic analysis of drug–drug interactions between isavuconazole and vincristine in pediatric subjects
por: Choules, Mary P, et al.
Publicado: (2023)

2537. Population Pharmacokinetics of Isavuconazole in Pediatric Patients
por: Desai, Amit, et al.
Publicado: (2023)

Pharmacokinetic Interaction Between Isavuconazole and a Fixed‐Dose Combination of Lopinavir 400 mg/Ritonavir 100 mg in Healthy Subjects
por: Yamazaki, Takao, et al.
Publicado: (2016)

Pharmacokinetics and Bioequivalence of Isavuconazole Administered as Isavuconazonium Sulfate Intravenous Solution via Nasogastric Tube or Orally in Healthy Subjects
por: Desai, Amit, et al.
Publicado: (2021)

Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials
por: Andes, David R., et al.
Publicado: (2018)

Pharmacokinetic and Pharmacodynamic Evaluation of the Drug‐Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects
por: Desai, Amit, et al.
Publicado: (2016)

Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole
por: Kovanda, Laura L., et al.
Publicado: (2017)

Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment
por: Desai, Amit, et al.
Publicado: (2016)

Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects
por: Yamazaki, Takao, et al.
Publicado: (2016)

Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?
por: Cojutti, Pier Giorgio, et al.
Publicado: (2021)

Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects
por: Yamazaki, Takao, et al.
Publicado: (2016)

No Dose Adjustment for Isavuconazole Based on Age or Sex
por: Desai, Amit V., et al.
Publicado: (2019)

Pharmacokinetic Assessment of Drug‐Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults
por: Groll, Andreas H., et al.
Publicado: (2016)

Pharmacokinetic Evaluation of CYP3A4‐Mediated Drug‐Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults
por: Townsend, Robert, et al.
Publicado: (2016)

Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection
por: Al-Shaer, Mohammad H., et al.
Publicado: (2019)

Isavuconazole Pharmacokinetics and Pharmacodynamics in Children
por: Elhence, Hirsh, et al.
Publicado: (2022)

Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure‐Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin‐Mediated (hATTR) Amyloidosis
por: Zhang, Xiaoping, et al.
Publicado: (2019)

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
por: Bader, Justin C., et al.
Publicado: (2018)

1396. Predictions of Isavuconazonium Sulfate Dosage in Patients Aged 6 Months: <18 Years by Physiologically Based Pharmacokinetic Modeling
por: Desai, Amit, et al.
Publicado: (2018)

Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data
por: Lakota, Elizabeth A., et al.
Publicado: (2018)

Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections
por: Li, Dan, et al.
Publicado: (2021)

Two Phase 1, Open‐Label, Mass Balance Studies to Determine the Pharmacokinetics of (14)C‐Labeled Isavuconazonium Sulfate in Healthy Male Volunteers
por: Townsend, Robert, et al.
Publicado: (2017)

Membrane Traffic in Aspergillus oryzae and Related Filamentous Fungi
por: Higuchi, Yujiro
Publicado: (2021)

1149. Baseline Chest CT Findings in Patients with Pulmonary Mold Infections: A Post-Hoc Analysis from the Phase 3 SECURE Study that Compared Isavuconazole to Voriconazole for the Primary Treatment of Invasive Mold Disease
por: Hamed, Kamal, et al.
Publicado: (2020)

Therapeutic efficacy of isavuconazole in experimental Aspergillus fumigatus endophthalmitis
por: Guest, John, et al.
Publicado: (2017)

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer
por: Appels, N M G M, et al.
Publicado: (2008)

Colistin and Isavuconazole Interact Synergistically In Vitro against Aspergillus nidulans and Aspergillus niger
por: Schwarz, Patrick, et al.
Publicado: (2020)

A Phase 1 Study To Assess the Pharmacokinetics of Intravenous Plazomicin in Adult Subjects with Varying Degrees of Renal Function
por: Komirenko, Allison S., et al.
Publicado: (2018)

Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study
por: Overcash, J. Scott, et al.
Publicado: (2019)

QT Interval Shortening With Isavuconazole: In Vitro and In Vivo Effects on Cardiac Repolarization
por: Keirns, J, et al.
Publicado: (2017)

Biotransformation of Progesterone by Whole Cells of Filamentous Fungi Aspergillus brasiliensis
por: Hosseinabadi, Tahereh, et al.
Publicado: (2015)

Variability and exposure–response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases
por: Kaindl, Thomas, et al.
Publicado: (2019)

Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
por: Arrieta, Antonio C., et al.
Publicado: (2021)

Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies
por: Hamed, Kamal, et al.
Publicado: (2023)

Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients
por: Bradley, John S., et al.
Publicado: (2016)

1320. Pharmacokinetics of Isavuconazole Administered as Isavuconazonium Sulfate Intravenous Solution via Nasogastric Tube or Orally in Healthy Volunteers
por: Desai, Amit, et al.
Publicado: (2020)

Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer
por: Royer, B, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_uqpnkgth6u96f7mh7pnevpjl4i